Ads
related to: treatments for age related macular degeneration- Wet AMD FAQs
Get Answers To Frequently Asked
Questions About Wet AMD
- Clinical Study Results
See The Results of A Clinical Study
To Learn More About This Treatment
- Download The Amsler Grid
Use This Test To Help Monitor
Your Vision Between Appointments
- Appointment Tips
Get Tips And Useful Information
To Talk To Your Specialist
- Financial Assistance
Learn About Financial Support
That May Be Available To You
- Resource Library
Useful Digital Resources & Tools
To Support Your Treatment Journey
- Wet AMD FAQs
Search results
Results From The WOW.Com Content Network
The incidence of age-related macular degeneration and its associated features increases with age and is low in people <55 years of age. [101] Smoking is the strongest modifiable risk factor. [102] As of 2008, age-related macular degeneration accounts for more than 54% of all vision loss in the white population in the US. [103]
In 2008, this study, called the Comparison of Age-Related Macular Degeneration Treatment Trials (CATT Study), enrolled about 1,200 patients with newly diagnosed wet AMD. The patients were assigned randomly to different treatment groups, and the data was collected from 2008 to 2009.
Conbercept, sold under the commercial name Lumitin, is a novel vascular endothelial growth factor (VEGF) inhibitor used to treat neovascular age-related macular degeneration (AMD) [1] [2] and diabetic macular edema (DME). [3] The anti-VEGF was approved for the treatment of neovascular AMD by the China State FDA (CFDA) in December 2013.
Induced pluripotent stem cell taken from blood cell and converted in retinal pigment epithelium. Stem cell therapy for macular degeneration is an emerging treatment approach aimed at restoring vision in individuals suffering from various forms of macular degeneration, particularly age-related macular degeneration (AMD). [1]
Argon, krypton, dye and diode lasers have been used with varying levels of energy to try to prevent age-related macular degeneration by eliminating drusen. A Cochrane review published in 2015 found that while laser treatment reduces drusen, there is no difference from placebo at 2 years with respect to preventing vision loss. [5]
At the end of the year, on December 17, the first intravitreal anti-VEGF drug pegaptanib (Macugen) was also licensed by FDA for treatment of wet age-related macular degeneration (wet AMD). [2] [9] Intravitreal injection has then become more common and a surge in the number of injections performed could be seen. [10]
Ad
related to: treatments for age related macular degeneration